Dupilumab significantly reduced exacerbations and improved lung function in adults with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation, based on data from more than ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. “Type 2 myocardial infarction occurs due to a mismatch ...

Researchers found that those with both type 2 diabetes and chronic obstructive pulmonary disease (COPD) had lower all-cause and respiratory-cause mortality survival probabilities than those without ...

Chronic obstructive pulmonary disease (COPD) is a group of diseases that affect the lungs. The disease makes it difficult to breath and progressively gets worse. About 15 million Americans have been ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The phase 3 BOREAS trial included adults with ...

Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, discusses improvements in lung function observed in patients enrolled in the BOREAS trial. The results of the BOREAS ...

Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug -- dupilumab -- that showed rapid and sustained improvements in patients in a pivotal Phase 3 ...

Researchers at the University of Pennsylvania have discovered a new type of cell in the human lung. Named respiratory airway secretory cells (RASCs), they seem to play a role in regenerating other ...

Chronic obstructive pulmonary disease (COPD) is a group of respiratory conditions that include emphysema and chronic bronchitis. It can cause symptoms such as: shortness of breath frequent respiratory ...